TCTMD’s Top 10 Most Popular Stories for May 2019
From in-depth features to an FDA alert and fresh data, TCTMD had the bases covered this month.
On-the-ground meeting coverage from EuroPCR and HRS dominated TCTMD’s most-read stories of May 2019. That said, the two top slots had nothing to do with the cardio conference circuit. Up first is a story on a US Food and Drug Administration alert about pacemaker battery depletion. Next comes TCTMD’s first-ever investigative feature—with office-based interventions on the rise, how can we align the interests of healthcare systems, physicians, and patients? Also on the list: another feature, which asks whether stents are always a must in MI patients, as well as news on cardiac-arrest warning signs.
So far, the batteries of three devices have drained prematurely, leading to the death of one pacemaker-dependent patient.
Doctors, payers, patients: all stand to gain as endovascular procedures shift to outpatient offices. Debate about oversight is just beginning.
This post hoc analysis of what was a negative trial should be considered hypothesis-generating, experts agreed.
Future studies should look at unexpected, noncardiac symptoms in an effort to target patients before it’s too late, an author says.
It’s been 30 years since the humble beginnings of this now flashy meeting, but the future is forward, not back, says William Wijns.
The transcatheter approach offers promise for the valve long neglected by interventional cardiologists due to a lack of options.
Experts caution that a mortality difference, if it exists, must be borne out in adequately powered trials.
A news headline sparked a Twitter outcry, but some say the best tactic for plaque erosion seen on OCT needs sober consideration.
Data from the RCT are bolstered by SCAAR registry findings that hint at a real-world ultrathin advantage.
The findings from the small, sham-controlled TREAT AF trial represent “a pretty exciting proof of concept,” one expert says.